The DEEP project has received research funding from the European Union under the 7th Framework Programme

News

DEEP joins Rare Disease Day in making the voice of rare diseases heard!

Febbraio 10, 2016
|
Comments off
|

The 29th February, 2016 marked the ninth international Rare Disease Day coordinated by EURORDIS . The main objective of Rare Disease Day was to raise awareness amongst the general public and decision-makers about rare diseases and their impact on patients’ lives. The campaign targeted primarily the general public […]

Share
Read more →

The Italian Multiregional Thalassemia Registry: centers characteristics, services and patients’ population

Febbraio 10, 2016
|
Comments off
|

Consorzio per Valutazioni Biologiche e Farmacologiche’s research activity in the pharmacological field is much diversified and it is mainly conducted in the context of national and EU level. It is focused on the development and application of innovative methodologies in clinical trials on small populations, the management […]

Share
Read more →

Medical care and transition phase of thalassemia in different countries: the ICET-A experience

Febbraio 5, 2016
|
Comments off
|

During the last Enpr-EMA (European Network of Paediatric Research at the European Medicines Agency) workshop, held in May 2015, adhering networks have been invited to provide a feedback on published guidance documents on the topic of transition from paediatrics to adults clinical care settings within the long […]

Share
Read more →

What is the minimum dose to start the IMPs?

Gennaio 26, 2016
|
Comments off
|

The starting dose for Deferiprone is 75 mg/kg/day, and for Deferasirox 20 mg/kg/day of DFX. Furthermore to avoid a disadvantage for patients who have reached higher doses prior to randomization, the starting dose can equal the previous one but only if it is within […]

Share
Read more →